hit identification

Views & Analysis

The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion.

News

Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.